TRT and Acne — Why Can Testosterone Cause Skin Problems?

In our broad article on hair loss, acne, and gynecomastia on TRT, we devoted a few paragraphs to acne — enough to debunk the myth that it's an unavoidable effect of therapy, but far too short to exhaust the topic. And of the three skin-and-hormone concerns, acne is the most common one: it affects a genuinely measurable share of men on TRT, varies most strongly by the form of hormone administration, and — as good news — has one of the best-understood biological mechanisms among all of testosterone therapy's side effects. That's exactly why it deserves separate, in-depth treatment: the full mechanism at the sebaceous-gland level, an honest comparison of administration forms, a realistic timeline of what to expect, and a concrete, staged treatment ladder — from cosmetics to a dermatologist's prescription.

If you're looking for an answer to 'does TRT always cause acne, and is that a myth', this article assumes you already know the answer (no, not always) and want to know more: why exactly this happens at the cellular level, why injections differ from gel, how long it lasts, and what to actually do once the problem appears. You'll find the broader roundup of myths and facts about acne, hair loss, and gynecomastia on TRT in our article 'Does TRT cause hair loss, acne, and gynecomastia? Facts vs. myths' — here we go deeper into skin alone.

Every hair follicle on the skin (except on the palms and soles) is connected to a sebaceous gland — a microscopic secretory structure whose job is to produce sebum, an oily substance that moisturizes and protects the skin. The cells that make up the sebaceous gland, called sebocytes, carry androgen receptors on their surface — proteins that bind circulating male sex hormones and, once bound, move into the cell nucleus, where they switch on the genes responsible for sebocyte maturation and lipid production. Testosterone can bind this receptor directly, but within the sebaceous gland itself, the enzyme 5-alpha-reductase type 1 is active, locally converting some testosterone into dihydrotestosterone (DHT) — a form with several times stronger affinity for the androgen receptor. This local conversion matters a great deal: it's not just about how much testosterone is circulating in the blood, but how much of it gets converted into the more potent DHT directly in the acne-affected skin.

The scale of this local conversion is significant — in acne-affected skin, 5-alpha-reductase activity and the conversion of testosterone to DHT are many times higher than in healthy skin, which partly explains why some body areas (face, back, chest — sites with the naturally highest density and activity of sebaceous glands) are far more prone to acne changes than others, despite an identical blood testosterone level throughout the body. A sebocyte stimulated by androgens increases not just the amount of sebum it produces, but also changes its composition — the share of certain fatty acids that promote inflammation and bacterial growth rises. This excess of denser, more of-these-fractions-rich sebum, combined with accelerated abnormal keratinization of the epithelium lining the follicle opening (a second, equally important effect of androgens on skin), leads to blockage of the follicle opening — that's the microcomedone, the earliest, invisible-to-the-eye acne lesion.

A blocked, lipid-rich hair follicle becomes an anaerobic environment, exceptionally favorable to the growth of Cutibacterium acnes (formerly classified as Propionibacterium acnes) — a natural skin resident that under normal conditions causes no problems, but in excess sebum and with blocked drainage starts multiplying rapidly, breaking down sebum lipids into irritating free fatty acids and activating the local immune system. It's this inflammatory response — not the follicle blockage itself — that turns an invisible microcomedone into a visible, often painful papule or pustule. This entire chain: androgen → sebocyte receptor → more and different sebum → blocked follicle → C. acnes proliferation → inflammation, is today recognized as the central pathophysiological mechanism of acne vulgaris, regardless of whether the androgen excess comes from natural puberty, polycystic ovary syndrome, or testosterone therapy.

A sebocyte responds to the androgen concentration available at that moment — and that concentration looks completely different in a man on TRT depending on the form of administration. Injectable testosterone (especially shorter-acting esters, given less often — once every one or two weeks at a larger single dose) creates a classic peak-and-trough profile: the hormone level in the blood rises sharply within the first day after injection, reaches a clear peak well above the target physiological level, and then gradually falls until the next injection, when the level is at its lowest. So the sebocyte sees not a stable, moderate hormonal signal, but a repeating impulse every several days to two weeks, significantly stronger than the average concentration would suggest on paper — and it's exactly this amplitude and frequency of impulses, not just the average hormone concentration over time, that most strongly drives sebum production.

Transdermal gels, patches, and extended-release preparations work on a completely different principle — they aim to mimic a physiological, relatively stable testosterone concentration throughout the day, without sharp peaks. Daily gel application keeps the hormone level within a narrow, predictable band, close to a healthy man's natural daily rhythm — without the sharp spikes that most irritate the sebaceous glands. That's why, in clinical practice and cohort-study data, injectable preparations consistently show up with a higher frequency and greater severity of acne than transdermal forms, at the same target physiological testosterone dose.

Acne related to starting TRT has a fairly characteristic, predictable timeline, though — importantly and honestly — it isn't identical for everyone. In most men, skin changes appear or worsen in the first 4-12 weeks of therapy, as the body moves from a lower (hypogonadal) androgen level to the target, higher physiological level — it's this relative jump, not the target level itself, that most strongly stimulates sebaceous glands that had spent months or years functioning in a low-testosterone environment and must suddenly adapt to a new hormonal signal.

In many men, over the following months — usually in a 6-12 month window from the start of therapy — acne severity spontaneously decreases, even without any change in dose or administration form. This probably happens for several reasons at once: the sebaceous glands partly adapt to the new, stable hormone level, the skin microbiome and local inflammatory response also equilibrate, and the body settles into a new balance point for converting testosterone to DHT in skin tissue. This stabilization isn't guaranteed for everyone, though — in some men, particularly those with a history of teenage acne or high individual 5-alpha-reductase activity in skin, changes may persist longer or recur cyclically in step with the dosing rhythm, as described above with injections.

The good news is that TRT-related acne doesn't require any special, separate treatment protocol — it responds to the same, well-studied dermatological methods as acne from other hormonal causes. The key is a staged approach: start with the simplest, safest interventions and escalate only when they're genuinely needed, rather than reaching for the strongest available drugs right away.

For moderate-to-severe cases, a dermatologist has further tools available: oral antibiotics (most often from the tetracycline class, usually used for a few months, never as lifelong therapy due to the risk of bacterial resistance) typically combined with topical treatment, and — in the most severe cases resistant to other treatment — isotretinoin, a drug with very high efficacy for severe acne, acting simultaneously on sebum production, follicle keratinization, and inflammation. Isotretinoin, however, requires especially careful coordination alongside ongoing testosterone therapy: regular bloodwork is needed (including a lipid and liver panel, which is monitored anyway on TRT, so there's partial overlap), and the decision to start it should be made by a dermatologist aware of the patient's full pharmacological picture, ideally in contact with the TRT-treating doctor. This isn't a drug to reach for on your own or treat as a first choice — but in warranted, severe cases, it's a real, proven option that shouldn't be avoided merely because the patient is simultaneously on hormone therapy.

In the vast majority of cases, the goal is a single one: manage the acne while continuing testosterone therapy unchanged, because TRT's benefits (improved energy, libido, muscle mass, mood, bone density) usually far outweigh the inconvenience of skin changes, which can be treated in parallel. Changing the testosterone dose or administration form purely because of acne is a rare option, reserved for situations where the lesions are genuinely severe, clearly resistant to the full dermatological treatment ladder (including specialist consultation and prescription medication), and meaningfully lower quality of life or risk permanent scarring.

In such statistically rare cases, two changes tend to be genuinely effective: switching from short-acting injections to a form with a more stable release profile (gel, patch, long-acting injections, or more frequent, smaller injection doses that flatten the peak), or, as a last resort, lowering the target testosterone level into the upper-middle instead of the upper end of the reference range, if the previous dosing was aiming for high physiological values. Both decisions belong solely to the treating doctor and need to be weighed against other therapy goals (e.g. if a higher testosterone level was deliberately chosen for hypogonadism symptoms, lowering the dose might partly bring them back) — this isn't a decision to make on your own out of frustration with your skin.

Acne on TRT has a clear, well-documented mechanism: androgens stimulate receptors in the sebaceous glands, increasing sebum amount and altering its composition, and local conversion of testosterone to the more potent DHT makes the skin respond more strongly than the blood hormone concentration alone would suggest. Risk and severity depend clearly on the administration form (injections, with their concentration peaks, usually produce stronger changes than more stable gels or patches) and the phase of therapy (usually worst in the first months, tending to stabilize over six months to a year). Most importantly, practically speaking: this is a treatable problem, with a staged, well-studied treatment ladder from basic skincare to dermatological treatment, which in the vast majority of cases allows a beneficial hormone therapy to continue without having to abandon it purely because of skin condition.